Generation of tunable glycosaminoglycan hydrogels to mimic extracellular matrices.
Herrero-Mendez A., Palomares T., Castro B., Herrero J., Alonso-Varona A.
Animal Study, published in J Tissue Eng Regen Med (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Tissue Eng Regen Med (2014)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24599800
- DOI
- 10.1002/term.1883
Abstract (original English)
Biomaterials and, especially, scaffolds may function as temporary extracellular matrix (ECM), mimicking in vivo environmental structures and facilitating cell growth and tissue regeneration. ECM is composed mostly of glycosaminoglycans (GAGs) and proteins, the ratio of GAGs, hyaluronic acid (HA):sulphated GAGs (sGAGs) being characteristic of each type of tissue. Umbilical cord (UC) and particularly Wharton's jelly (WJ) have been proposed as good sources for obtaining GAGs. In this work, we present a novel methodology for the extraction, purification and separation of GAGs from UC obtained from two different species, human and pig. The new methodology is based on enzymatic digestion of WJ, precipitation of GAGs with organic solvents, purification steps and chromatographic separation of GAGs using ion exchange columns. This novel process allows highly purified HA and sGAGs to be obtained from human and pig WJ. The composition of sGAGs and molecular weight of HA were very similar in the two species and GAGs are haemocompatible and non-cytotoxic. Finally, these new biomaterials have significant bioactive properties, increasing proliferation rates of two cell lines, human adipose mesenchymal stem cells (ASCs) and fibroblasts. In summary, the separation of HA and sGAGs, linked to the improvement in the GAG quantification method described in this paper, opens new avenues for the formu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.